Health ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Obesity Treatments Monoclonal Antibodies Alzheimer's Disease Combination Therapy Eli Lilly Immunotherapy Novo Nordisk GLP-1 Drugs Oncology

3 ARTICLES

yesterday

FDA Approves Lumvoa for Thyroid Eye Disease

Supported by two positive Phase 3 trials, the approval lets Viridian begin commercial sales, activate a patient-access program, and pursue coverage for people with active or chronic disease.

10 ARTICLES

2d ago

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

4 ARTICLES

4d ago

EMA Committee Recommends Revoking Tavneos Authorization

6 ARTICLES

4d ago

Lawmakers Demand Answers After Single Patient Received Experimental Eli Lilly Obesity Drug

3 ARTICLES

5d ago

Trodelvy Approved in U.S. and EU as First‑Line Option for Metastatic Triple‑Negative Breast Cancer

4 ARTICLES

last wk.

FDA Grants Accelerated Approval to Sanofi’s Tzield for Children With Stage 3 Type 1 Diabetes

3 ARTICLES

2w ago

Nonprofit Buys Experimental Leukemia Drug to Keep Pediatric Access Open

3 ARTICLES

2w ago

Novartis Says Del‑brax Study Met Endpoints and Reinforced Phase 3 Dosing

11 ARTICLES

2w ago

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

9 ARTICLES

2w ago

Experimental Antibody Preserves Muscle During Tirzepatide Weight Loss

45 ARTICLES

3w ago

Pfizer’s Once‑Monthly GLP‑1 Shows Strong Weight Loss but Raises Dosing‑Safety Questions

9 ARTICLES

3w ago

Roche and Nurix Strike $700M Deal to Co‑Develop Oral BTK Degrader Bexobrutideg

4 ARTICLES

3w ago

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

4 ARTICLES

3w ago

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

7 ARTICLES

3w ago

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Drug Development

FDA Approves Lumvoa for Thyroid Eye Disease

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

EMA Committee Recommends Revoking Tavneos Authorization

Lawmakers Demand Answers After Single Patient Received Experimental Eli Lilly Obesity Drug

Trodelvy Approved in U.S. and EU as First‑Line Option for Metastatic Triple‑Negative Breast Cancer

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

Eli Lilly's GLP‑1 Surge Leaves Pfizer as the High‑Yield Option

Pakistan Genome Resource Maps Thousands of Human Gene Knockouts

Ocular Therapeutix Plans Q4 Filing for AXPAXLI After Reported FDA Alignment

Neumora Halts Navacaprant After Phase 3 KOASTAL Failures

Never miss stories about

Drug Development

FDA Grants Accelerated Approval to Sanofi’s Tzield for Children With Stage 3 Type 1 Diabetes

Nonprofit Buys Experimental Leukemia Drug to Keep Pediatric Access Open

Novartis Says Del‑brax Study Met Endpoints and Reinforced Phase 3 Dosing

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

Experimental Antibody Preserves Muscle During Tirzepatide Weight Loss

Pfizer’s Once‑Monthly GLP‑1 Shows Strong Weight Loss but Raises Dosing‑Safety Questions

Roche and Nurix Strike $700M Deal to Co‑Develop Oral BTK Degrader Bexobrutideg

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Never miss stories about

Drug Development